Toolkit
The MSL Toolkit — 5 Ready-to-Use Frameworks
Ready-to-use structures for the five conversations Medical Science Liaisons have most often — built for accuracy, credibility, and clinical impact.
Published by VarsaAI | For Medical Science Liaison teams across pharma and biotech
How to Use This Toolkit
Each framework provides a complete structural template for a specific MSL scenario — including slide-by-slide guidance, key messages, language prompts, and a pre-meeting checklist. Use them as starting points and adapt to your therapeutic area, audience, and data set.
Select the framework that matches your upcoming engagement scenario.
Review the purpose box to confirm the framework fits your objective and audience.
Use the slide-by-slide structure as your content blueprint. Adapt with your data.
Complete the pre-meeting checklist before every engagement.
Contents — Five Frameworks at a Glance
- 01Clinical Data Dissemination— Medical Affairs
- 02Competitive Landscape Review— Commercial Support
- 03Disease Education Module— HCP Engagement
- 04KOL Scientific Exchange— Peer-to-Peer
- 05Congress Debrief— Post-Congress
Clinical Data Dissemination
Structured for communicating primary trial data, subgroup analyses, or new publication findings to HCPs in a balanced, scientifically rigorous format.
Primary Objective
Accurately communicate the key findings of a clinical trial or publication in a way that is contextually meaningful to the HCP's clinical practice.
Ideal Audience
Specialist HCPs with existing familiarity with the disease area — cardiologists, oncologists, rheumatologists, neurologists.
Success Looks Like
The HCP understands what the data means for their patients, asks substantive questions, and requests the full publication or further follow-up.
Slide-by-Slide Structure
1.Setting the Scene — Why This Data Matters Now
Open with a brief framing of the unmet need or clinical question this study addresses. Ground the physician in the 'why' before the 'what.'
- 1–2 sentences max
- Reference patient population
- No data on this slide
2.Study Design Overview
Present the study design clearly — population, intervention, comparator, endpoints, and duration. Use a visual schematic rather than a text-heavy description.
- CONSORT-style diagram
- Highlight primary endpoint
- Flag key inclusion/exclusion criteria
3.Baseline Characteristics
Establish the patient population studied. Help the HCP determine whether the trial population is relevant to their own patients.
- Table format preferred
- Highlight any imbalances
- Compare to real-world demographics where possible
4.Primary Endpoint Results
Present the primary efficacy endpoint clearly and completely — including confidence intervals, p-values, and the clinical meaning of the result.
- Forest plot or KM curve
- Report both relative and absolute risk reduction
- Include 95% CI
5.Secondary Endpoints & Supporting Data
Present secondary endpoints in order of clinical relevance, not statistical strength. Flag which endpoints were pre-specified versus exploratory.
- Clearly label pre-specified vs exploratory
- Avoid p-hacking narrative
- Use consistent visual format
6.Subgroup Analyses
Present pre-specified subgroup data with appropriate caution. Focus on subgroups most relevant to the HCP's patient population.
- Forest plot format
- State clearly if pre-specified
- Do not over-interpret
7.Safety & Tolerability
Present the complete safety profile — not just favourable data. Include discontinuation rates, serious adverse events, and events of special interest.
- Adverse event table
- Include all grades
- Compare to control arm
8.Study Limitations
Proactively address the key limitations of the study. Naming limitations before the HCP does builds enormous credibility.
- 3–5 bullet points maximum
- Your limitations, honestly stated
- Discuss what they mean in practice
9.Clinical Context & Implications
Help the HCP situate the findings within the broader treatment landscape and their own clinical practice.
- Avoid promotional language
- Use 'the data suggests' framing
- Invite the HCP's interpretation
10.Discussion & Questions
End with a deliberate invitation to dialogue. The best data dissemination conversations end with the HCP asking questions, not the MSL making statements.
- 3 open questions prepared
- Have full publication ready
- Note any follow-up agreed
Sample Opening
"I wanted to share some data with you today that I think is directly relevant to a specific patient group you'll recognise — patients who've already failed first-line therapy but still have good performance status. There's been a long-standing question in the literature about whether we're doing enough for this population. The AURORA trial, published last month in the NEJM, addresses that question directly. I'd love to walk you through the findings and get your perspective on what they mean in practice."
What to Prepare Before the Meeting
- Full publication or preprint accessible offline
- Know the HCP's patient population and likely patient types
- Prepare answers to the three most likely critical questions
- Have subgroup data relevant to this HCP's practice type
- Know the current treatment guideline status
Common Objections & How to Address Them
MSL Pro Tips
Lead with the limitation
Naming a study's biggest weakness before the HCP does is the single most credibility-building move an MSL can make.
Absolute over relative
Always present absolute risk reduction alongside relative. An experienced HCP will call out relative figures presented without context.
Less is more
If you can't communicate the most important finding in one clear sentence without a slide, you haven't understood it well enough yet.
Pre-Meeting Checklist
- I know the primary and key secondary endpoints by memory
- I can state both relative and absolute risk reduction without looking at slides
- I have reviewed the safety table in full, including all-cause discontinuations
- I know which subgroups are pre-specified vs exploratory
- I have prepared my three-sentence summary of study limitations
- I have two or three open questions to invite the HCP's perspective
- I have the full publication available if requested
- I know this HCP's patient mix and have the most relevant subgroup data
Competitive Landscape Review
A balanced, evidence-based overview of the treatment landscape — helping HCPs understand where different therapeutic options sit relative to each other, without crossing into promotional territory.
Primary Objective
Provide an objective, data-driven overview of the treatment options available in a specific indication — enabling the HCP to make more informed prescribing decisions.
Ideal Audience
HCPs actively navigating treatment decisions in a competitive or rapidly evolving therapeutic area. Particularly valuable at indication launch or post-approval label expansion.
Success Looks Like
The HCP has a clearer framework for how they think about treatment selection. They ask questions about specific patient scenarios and request additional data.
Slide-by-Slide Structure
1.The Clinical Decision Problem
Open by articulating the clinical challenge. Frame the landscape as a decision problem, not a product comparison.
2.Disease Burden & Unmet Need Snapshot
A brief, data-referenced overview of the disease burden and residual unmet need that the current treatment landscape has not fully addressed.
- Cite epidemiology data
- Reference current outcomes data
- Keep to 2–3 data points
3.Treatment Landscape Overview
A visual map of current treatment options — organised by line of therapy, mechanism of action, or patient population subgroup. Include all relevant options — not just your own.
- Include all approved options
- Organise by mechanism or line of therapy
- Landscape diagram or table
4.Head-to-Head Evidence Summary
Where head-to-head trial data exists, present it. Where it does not, be explicit about the limitations of cross-trial comparisons.
- Be transparent about indirect comparisons
- Present in comparative table
- Acknowledge heterogeneity in trial designs
5.Patient Profiling — Matching Treatment to Patient
Provide a framework for thinking about which patients are most likely to benefit from which therapeutic approach.
- Decision tree or patient persona format
- Evidence-based differentiation
- Invite the HCP to share their own patient cases
6.Real-World Evidence Supplement
Where available, supplement trial data with real-world evidence — particularly for populations underrepresented in pivotal trials.
7.Emerging Data & Pipeline Overview
Provide a brief, balanced view of what is coming in the landscape — ongoing trials, expected data readouts, and pipeline agents.
- Include competitors' pipelines
- Reference clinicaltrials.gov
- Be balanced and accurate
8.Discussion — Treatment Decision Framework
Facilitate a dialogue around how the HCP currently approaches treatment selection and whether any of the data presented changes their thinking.
Sample Opening
"I want to be upfront — I've included all of the approved options here, not just our product. My goal is to give you a complete picture of what's available so we can have a meaningful conversation about where the evidence is strongest and where the gaps still exist. I'll flag clearly when I'm talking about direct evidence versus cross-trial comparisons, because I know those are very different things."
Critical Rules for This Framework
- →Include all approved therapeutic options — not just your own product
- →Never present indirect comparisons as equivalent to head-to-head data
- →Flag every data limitation proactively, including your own product's gaps
- →Let the data do the differentiation — do not narrate it
- →If you don't know, say so. Then follow up with the correct information
Questions to Invite Discussion
- →"Which patient type do you find most difficult to make a treatment decision for?"
- →"Where do you feel the current evidence leaves the biggest gap?"
- →"Have you seen patient outcomes that surprised you relative to the trial data?"
- →"What would you need to see to change your current approach in this population?"
MSL Pro Tips
Credibility through completeness
An MSL who presents a landscape that includes their competitors' best data — fairly represented — is trusted infinitely more than one who doesn't mention them.
The indirect comparison trap
Never let an indirect comparison do the work of head-to-head data. If the HCP pushes for a direct comparison where none exists, say exactly that.
End with their decision
The goal is not to tell the HCP what to prescribe. It is to give them a better framework for making that decision themselves.
Pre-Meeting Checklist
- I know the approved indications for all relevant competitors
- I have reviewed the most recent competitor label and key trial publications
- I know which head-to-head trials exist and which do not
- I know this HCP's current prescribing patterns in this indication
- I can articulate why indirect comparisons are limited without being dismissive
- I have 3 patient scenario questions ready to facilitate discussion
Disease Education Module
A structured educational framework for HCPs entering a new therapeutic area or seeking to deepen their understanding of disease biology, diagnosis, and the implications for treatment.
Primary Objective
Elevate the HCP's understanding of disease pathophysiology, diagnostic criteria, and patient identification — independent of any specific treatment discussion.
Ideal Audience
HCPs who are newer to the therapeutic area, GPs who refer into specialist care, or specialists expanding into an adjacent indication. Also valuable for nurse practitioners and pharmacists.
Success Looks Like
The HCP identifies gaps in their current diagnostic or referral practice. They request additional educational resources or follow-up on a specific aspect of disease biology.
Slide-by-Slide Structure
1.The Patient Who Falls Through the Gap
Open with a brief patient vignette that encapsulates the diagnostic or management challenge this module addresses. Ground abstract biology in a recognisable clinical scenario before presenting any science.
- Brief, realistic patient case
- Do not reveal diagnosis yet
- Let the HCP engage with the diagnostic question
2.Epidemiology & Disease Burden
Establish how common, how serious, and how underdiagnosed the condition is. Use local or regional data where available.
- Incidence and prevalence data
- Time-to-diagnosis statistics
- Misdiagnosis rates where available
3.Pathophysiology — The Biological Story
Walk through the key biological mechanisms that drive the disease. Use visual pathways and stepwise builds rather than dense text.
4.Clinical Presentation & Phenotypes
Describe the spectrum of clinical presentations — from classic to atypical. Highlight patient subgroups who are most likely to be misdiagnosed or underdiagnosed.
5.Diagnostic Criteria & Challenges
Present the current diagnostic criteria clearly, including any recent guideline updates. Discuss the practical challenges of diagnosis in clinical practice.
- Reference current guidelines
- Include differential diagnosis
- Highlight diagnostic pitfalls
6.Patient Identification — Spotting Who to Screen
Give the HCP a practical framework for identifying which patients in their practice should be screened or referred.
- Risk factor checklist
- Validated screening tool if available
- Referral pathway guidance
7.Impact of Late or Missed Diagnosis
Contextualise the clinical and patient consequences of delayed diagnosis — disease progression, quality of life impact, economic burden, and mortality where relevant.
8.Return to Patient Vignette — Discussion
Return to the opening patient case and invite the HCP to discuss how they would now approach diagnosis and management.
- Ask what they would do next
- Invite reflection on their own practice
- Avoid providing 'the answer' too quickly
9.Summary & Educational Resources
Close with a clear summary of the two or three most important clinical takeaways, and offer access to additional educational resources.
Sample Opening
"I want to start with a patient rather than a slide deck. She's 54. She came in complaining of fatigue and intermittent joint pain — nothing you wouldn't see a dozen times a week. She'd seen three other physicians over 18 months. Each one had run bloods, found nothing dramatic, and reassured her. By the time she was correctly diagnosed, she'd lost two years. I want to explore today why that gap happens so often — and what we can do about it."
MSL Pro Tips
Biology before treatment
Never introduce your product in a disease education module. The moment treatment is mentioned, you've changed the nature of the conversation — and often lost the HCP's trust in the education itself.
The vignette is not decorative
A well-chosen patient case does more educational work than ten slides of epidemiology. Choose it carefully to represent the diagnostic challenge most likely to resonate with this HCP.
Make it local
Wherever possible, use regional or national epidemiology data. An HCP responds differently to local prevalence data than to a global figure. Localisation transforms relevance.
Pre-Meeting Checklist
- I have selected a patient vignette appropriate to this HCP's practice setting
- I have local or national epidemiology data, not just global figures
- I know the current diagnostic guidelines, including any recent updates
- I have not included any product-specific content in this module
- I can explain the pathophysiology clearly without slides if needed
- I have additional educational resources ready to leave or share digitally
KOL Scientific Exchange
A structured framework for high-value, peer-to-peer scientific discussions with Key Opinion Leaders — focused on genuine exchange, emerging evidence, and collaborative thinking.
Primary Objective
Engage a KOL in substantive scientific dialogue — gathering insights on unmet needs, emerging evidence, and research priorities while sharing relevant data from your programme.
Ideal Audience
Established thought leaders, academic clinicians, guideline committee members, or clinical researchers with deep expertise and active involvement in shaping the therapeutic area.
Success Looks Like
A genuine two-way conversation where the KOL shares substantive insights that advance your understanding of the field — and where the MSL listens more than they speak.
Slide-by-Slide Structure
1.Agenda — Set as a Conversation, Not a Presentation
Frame the meeting explicitly as a scientific exchange, not a data presentation. Show an agenda that allocates substantial time to discussion. KOLs disengage rapidly from meetings that feel like one-way briefings.
- Minimum 40% of time allocated to discussion
- Name specific topics you want their perspective on
- Ask if they want to add anything to the agenda
2.Context — Why This Conversation, Why Now
Briefly articulate what has changed in the field — a new publication, a recent congress presentation, an upcoming data readout — that makes this conversation timely.
3.Data Snapshot — The Evidence You Want to Discuss
Present a focused summary of the specific data set you want the KOL's perspective on. This should be a starting point for discussion, not a comprehensive review.
- 2–3 slides maximum on data
- Present the most contested or nuanced findings
- Specifically flag where you want their interpretation
4.The Open Questions — Framing the Discussion
Present two or three specific, substantive scientific questions where you genuinely want the KOL's perspective. These should be areas of genuine scientific uncertainty or clinical debate.
- Questions should be genuinely open
- Avoid questions you already know the answer to
- These are the most important slides in this framework
5.Pipeline & Research Direction — Seeking Input
Share appropriate information about your research programme or upcoming studies, and explicitly invite the KOL's input on design, endpoints, or patient population.
- Only share information you are authorised to share
- Frame as seeking input, not seeking validation
- Have a clinical affairs contact available for follow-up
6.Summary of Insights — Closing the Loop
Close by summarising the key insights and perspectives the KOL has shared during the meeting. Confirm any follow-up actions and the timeline for next contact.
- Repeat their key points back to them
- Confirm what you will share internally
- Agree on next steps explicitly
Sample Opening
"I want to be clear from the outset — I'm not here to present a deck and walk you through our data. You know this field better than I do, and what I'm genuinely here for is your perspective on a set of questions that I don't think have clean answers yet. I've got a few slides to provide context, but I'd much rather spend most of our time on the things we actually disagree about. Is that a useful way to use this hour?"
Rules for KOL Engagement
- Listen more than you speak — target a 60/40 split in favour of the KOL
- Never present anything you are not authorised to share externally
- Take detailed notes — their insights have internal value
High-Value Open Questions
- →"Where do you think the field's biggest evidence gap still is?"
- →"What would you design differently if you were running the next pivotal trial?"
- →"Which patient subgroup do you think we understand least well?"
MSL Pro Tips
Fewer slides, deeper conversation
A KOL meeting with 8 slides and 40 minutes of genuine dialogue will always outperform a 20-slide presentation where you run out of time for questions.
Do your homework
Nothing signals respect for a scientist like knowing their work.
Capture everything
The insights shared in KOL meetings have enormous internal value. Capture them in detail and share them systematically.
Pre-Meeting Checklist
- I have read this KOL's three most recent publications
- I know their stated positions on key scientific debates in the field
- I have prepared 3 genuinely open scientific questions — not leading questions
- I have confirmed what information I am authorised to share externally
- I have a note-taking plan — I will capture their insights in real time
- I have allocated at least 40% of meeting time to discussion on the agenda
- I know what internal stakeholders need to hear from this conversation
- I have a follow-up email drafted, ready to send within 48 hours
Congress Debrief
A structured framework for synthesising and communicating the most clinically relevant data presented at a major congress — enabling HCPs to access curated congress intelligence without having attended.
Primary Objective
Provide a curated, clinically relevant summary of the most important data presented at a recent major congress — positioning the MSL as an indispensable source of curated scientific intelligence.
Ideal Audience
HCPs who did not attend the congress, or who attended but want a curated perspective on which data was most clinically significant. Particularly valuable in the two to four weeks immediately following a major meeting.
Success Looks Like
The HCP feels genuinely better informed. They engage with the data, ask questions about specific presentations, and request follow-up on particular findings.
Slide-by-Slide Structure
1.Congress at a Glance — The Headlines
Open with three or four bullet points summarising the most significant themes or paradigm-shifting findings from the congress as a whole.
- 3–4 headlines maximum
- Include competitor data if significant
- Set the tone for the congress as a whole
2.Late-Breaking Trials — The Most Important Data
Summarise the two or three late-breaking trial presentations most relevant to this HCP's practice. Include a brief methods summary, key findings, and your assessment of clinical significance.
- Lead with clinical significance
- Include one slide per major trial
- Mention whether findings are consistent with prior data
3.Key Abstracts & Posters — Supporting Evidence
Highlight two or three additional abstracts or poster presentations that add important context — subgroup analyses, biomarker data, real-world evidence, or quality-of-life findings.
4.Expert Panel & Debate Highlights
Summarise the most important perspectives from expert panels, debates, or symposia. What did thought leaders agree on? Where was there genuine disagreement?
- Attribute views accurately
- Represent all sides of any debate fairly
- Note where consensus is forming or fracturing
5.What This Means for Clinical Practice
Synthesise the congress findings into practical clinical implications — what should this HCP do differently, think about differently, or watch out for?
- 3–5 practice implications
- Be specific, not generic
- Acknowledge where evidence is not yet strong enough to change practice
6.What to Watch — Upcoming Data
Close with a forward-looking view of what data readouts are expected in the next 6–12 months that are likely to further shape the field.
- Include all relevant upcoming trials — not just your own
- Reference expected publication or congress timelines
- Offer to follow up when key data becomes available
7.Discussion — The HCP's Take
Invite the HCP's perspective on the congress findings. What surprised them? What concerns them? What would change their practice?
Sample Opening
"ESMO this year felt different from the last few — there were two late-breaking readouts that I think will genuinely move the conversation in this area, and one that I suspect will be controversial. I want to walk you through the three I think matter most for your patient population specifically — and I'm equally interested in whether you see it the same way I do, because there's a debate among the faculty that I don't think is settled."
Timing Is Everything
- Aim to deliver the debrief within 2–3 weeks of the congress closing
- Have a 'headlines' version ready within 48–72 hours for high-priority HCPs
- For HCPs who attended, focus on interpretation rather than summary
- Personalise to the HCP — emphasise data most relevant to their patient mix
What Makes a Great Congress Debrief
- Genuine curation — not a recitation of every abstract presented
- An editorial voice — your assessment of what matters and why
- Honesty about findings that complicate the narrative
- A forward view — what to watch for in the next 12 months
MSL Pro Tips
Curation over comprehensiveness
The HCP does not need every abstract. They need the three things that matter most for their patients, explained clearly by someone who was there. Be an editor, not an archivist.
Include the uncomfortable
If a competitor's data was the most significant finding at the congress, present it fairly and completely. Omitting it destroys credibility. Including it builds it.
Have an opinion
The most valuable congress debrief is one where the MSL offers a genuine, evidence-based perspective on what the data means — not just a neutral summary.
Pre-Meeting Checklist
- I have reviewed all late-breaking trial abstracts relevant to this HCP's area
- I can articulate what I think the clinical implications are in 2–3 sentences
- I have selected the 3 most clinically significant findings for this specific HCP
- I have the upcoming data readout calendar ready to share
- I have included all significant competitor data, not just our own
- I know whether this HCP attended the congress and have adapted accordingly
- I know which expert panel views were aligned and which were contested
- I have planned 2–3 questions to invite their perspective on the data
Scientific content that moves at the speed of science.
VarsaAI helps pharma teams turn data packages, publications, and congress findings into polished presentations and video in minutes — so your MSLs spend more time having conversations like these, and less time building slides.